Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

>All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

FINANCIAL TABLES FOLLOW  CEPHEID 

 

CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)

 Three Months Ended December 31, Years Ended
December 31, 2012201120122011Revenues:System sales

$  14,101$  20,371$   55,447$  61,948Reagent and disposable sales

75,55756,576266,101203,576Total product sales

89,65876,947321,548265,524Other revenues

2,7753,1679,66412,051Total revenues 

92,43380,114331,212277,575Costs and operating expenses:Cost of product sales 

42,89638,632153,365122,840Collaboration profit sharing 

1,4161,5827,1834,863Research and development

17,29916,65071,67359,362Sales and marketing

16,29414,49061,90750,691General and administrative

9,47010,15343,29836,004Litigation settlement

--15,110-Total costs and operating expenses 

87,37581,507352,536273,760Income (loss) from operations 

5,058(1,393)(21,324)3,815Other income (expense), net

241(506)(4)(1,143)Income (loss) before income taxes

5,299(1,899)(21,328)2,672Benefit from (provision for) income taxes

3452501,285(45)Net income (loss)

$
5,644$  (1,649)$ (20,043)$
2,627Basic net income (loss) per share 

$
.09$
(0.03)$
(0.30)$
.04Diluted net income (loss) per share 

$
.08$
(0.03)$
(0.30)$
.04Shares used in computing basic net income (loss) per share 

66,37064,11365,81262,735Shares used in computing diluted net income (loss) per share '/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
(Date:12/19/2014)... (HealthDay News) -- A new study suggests a possible ... hot flashes and night sweats -- and higher rates ... are common during menopause, affecting about 60 percent of ... after menopause, since they then face a higher risk ... women who exhibit moderate or severe menopausal symptoms are ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... December 17, 2014 Dr. Myo Nwe is ... Loss Diet of the Future” and co-founder of the Ace ... book, Dr. Nwe takes a broad look at the industry ... up under scientific scrutiny. On film and in television shows, ... mostly toward the social aspects and played for basic laughs, ...
(Date:12/17/2014)... San Francisco, CA (PRWEB) December 17, 2014 ... the Stanford Center for Longevity, today, in reaction to a ... the emerging science of brain training and derogated the efficacy ... said that they agreed with the parts of the center’s ... however, they believed the center had also overstated its case, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview of ... and Obamacare architect Jonathan Gruber to public attention. Award-winning ... which is being distributed on YouTube. , During the ... the Affordable Care Act in order to hide a ... per year tax grab. , “President Obama promised us ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... boost emotional well-being in hard times , , THURSDAY, May ... women may actually overspend to try to cheer themselves up, ... found that 79 percent said they,d go on a shopping ... listed "depression" and 60 percent listed "feeling a bit low" ...
... to Improve CBO Modeling and Information for PolicymakersWASHINGTON, ... Fight Chronic Disease policy briefing on Capitol Hill, ... James C. Capretta, M.A., released a white paper, ... Diseases: The Current Context and Potential Enhancements." ...
... Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group practice company, announced today that management ... New York City., ... ... ...
... CITY, Calif., May 21 Genomic Health, Inc. (Nasdaq: ... will present results from three studies at the American ... May 29 - June 2, 2009, at the Orange ... markets the widely-adopted Onco type DX(R) breast cancer ...
... 21 Celator Pharmaceuticals today announced that it ... Inc. (Nasdaq: CEPH ). The ... application of Celator,s proprietary technology to an ongoing ... agreement provides an opportunity to leverage the technology ...
... the importance of hearing healthPISCATAWAY, N.J., May 21 ... Hearing Month in Times Square from ... air a 30-second hearing loss awareness video every hour on ... addition, 18 Siemens representatives will be in Times Square and ...
Cached Medicine News:Health News:Shop 'Til You Drop: You May Feel Better 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:IPC The Hospitalist Company, Inc. to Present at Citi's 2009 Healthcare Services Day 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 2Health News:Siemens Promotes May is Better Speech and Hearing Month on America's Largest Stage 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
MONOJECT Red/Yellow Mottled Stopper...
BD Vacutainer® Specialty Tubes - Thrombin...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: